Gene Biotherapeutics, Inc.
Gene Biotherapeutics, Inc. (CRXM) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
crxm · pe ratio · data through Dec 31, 2020
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Gene Biotherapeutics, Inc. (CRXM) measures how much investors pay for each dollar of the company's trailing earnings. CRXM's current PE ratio of N/A is calculated by dividing its stock price of $0.00 by its TTM earnings per share of -$0.02.
Source: FMP · /ratios-ttm · /analyst-estimates · 2020-12-31
PE Ratio History
2001 – 2020 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Gene Biotherapeutics, Inc.You CRXM | $0M | N/A | — | -$0.02 |
 Acacia Diversified Holdings, Inc. ACCA | $0M | N/A | — | -$0.05 |
 American CryoStem Corporation CRYO | $0M | N/A | — | -$0.05 |
 E-Qure Corp. EQUR | $0M | N/A | — | -$0.02 |
 Capha Pharmaceuticals Inc. FPSUF | $0M | N/A | — | -$0.00 |
 Gelesis Holdings, Inc. GLSHQ | $0M | N/A | — | -$0.81 |
 Generex Biotechnology Corporation GNBT | $0M | N/A | — | -$0.46 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2020-12-31Latest FY2020 | — | $-0.02 | — | |
2019-12-31 FY2019 | 3.09x | $0.06 | — | |
2018-12-31 FY2018 | — | $-0.03 | — | |
2017-12-31 FY2017 | — | $-0.13 | — | |
2016-12-31 FY2016 | — | $-0.22 | — | |
2015-12-31 FY2015 | — | $-0.29 | — | |
2014-12-31 FY2014 | — | $-0.50 | — | |
2013-12-31 FY2013 | — | $-1.27 | — | |
2012-12-31 FY2012 | — | $-1.41 | — | |
2011-12-31 FY2011 | — | $-1.68 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Gene Biotherapeutics, Inc. (CRXM) measures how much investors pay for each dollar of the company's trailing earnings. CRXM's current PE ratio of N/A is calculated by dividing its stock price of $0.00 by its TTM earnings per share of -$0.02.
Frequently asked questions
CRXM pe ratio · 6 questionsCRXM's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.00 and TTM EPS of -$0.02. Data sourced from Financial Modeling Prep via CRXM's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Gene Biotherapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09